NFKB1 and Hyperglycemia: kinases (MAPKs) and NF-κB pathway activation (Yang et al,[26] 2023), which can reverse this process and form a synergistic inhibition of the NF-κB pathway with statins, thus maintaining the efficacy of IPN regulation under hyperglycemia (Li et al,[27] 2016), and has a good safety profile without serious adverse effects.